Sutro Biopharma, Inc. · NASDAQ:STRO
Sutro Biopharma — Investor Presentation (September 2024)
28 slides from Sutro Biopharma's investor presentation, September 2024
Slide 1: Science Designed to Provide Endless Possibility
Science Designed to Provide Endless Possibility September 2024 Sutro Biopharma NASDAQ: STRO 1 NON CONFIDENTIAL
Slide 2: Forward-Looking Statements
2 Forward-Looking Statements This presentation and the accompanying oral presentation contain “forward-looking” statements that are based on our management’s beliefs and assumptions and on information currently available to management. Forward-looking statements include all statements other than sta
Slide 3: Next-Generation ADCs and Biologics, Transforming Science for Patients
3 Next-Generation ADCs and Biologics, Transforming Science for Patients Luvelta Luvelta pipeline-in-a-drug potential with two registrational trials ongoing and multiple follow-on opportunities Proven Cell Free Discovery and Manufacturing Pipeline Platform Driving Three Emerging pipeline of next-gene
Slide 4: Sutro Pipeline Drives Broad Potential with Multiple Near-Term Catalysts
Sutro Pipeline Drives Broad Potential with Multiple Near-Term Catalysts Luvelta FRα-targeting ADC with Two Complementary Additional Luvelta Opportunities and Registrational Trials Next-Generation ADC Pipeline Ovarian Cancer (Fast Track Designation) Luvelta for Non-Small Cell Lung Cancer • Registrati
Slide 5: Partnerships Provide up to ~$3 Billion Potential Future Milestones plus Royalties
5 Partnerships Provide up to ~$3 Billion Potential Future Milestones plus Royalties Phase 2/3 vaccines Blackstone purchase of Phase 1 IL-2 cytokine STRO-003 (ROR1 ADC) Preclinical Exclusive license to for invasive 4% royalties on potential derivative for cancer preclinical program for immunostimulat
Slide 6: STRO-002 Luveltamab Tazevibulin (Luvelta)
STRO-002 Luveltamab Tazevibulin (Luvelta) 6 NON CONFIDENTIAL
Slide 7: Luvelta: Deliberate Design + Development Enables Pipeline-in-a-Drug Opportunity
Luvelta: Deliberate Design + Development Enables Pipeline-in-a-Drug Opportunity Precisely Designed ADC to Expand Potential to Address Multiple FRα Expressing Cancers, Patient Access Including those with Low Expression Levels Hemiasterlin payload • Promising clinical activity in all indications evalu
Slide 8: Significant Opportunities, Initially in Ovarian and Expanding to Additional FRα Expressing Cancers
Significant Opportunities, Initially in Ovarian and Expanding to Additional FRα Expressing Cancers Luvelta Potentially Doubles the Estimated Annual Incidence in FRα-Expressing Patient Populations Addressable PROC Patients (U.S., Europe and Japan) Percent of Ovarian Cancer Patients Eligible for Thera
Slide 9: Opportunity to be First Therapy for Broad PROC Patient Population
Opportunity to be First Therapy for Broad PROC Patient Population Treatment Eligibility is Driven Comparison of Potential Luvelta Population by FRα Biomarker Test with Approved ADC Population Luvelta has demonstrated clinical activity in PROC patients TPS Staining Intensity 1+ Staining Intensity 2+
Slide 10: Registrational Strategy Supported by Clinical Data from ~100 Patients
Registrational Strategy Supported by Clinical Data from ~100 Patients Maximum Reduction in Tumor Target Lesions in RECIST-Evaluable Patients (N=92 Evaluable) 20% 3 in 5.2, 2 in 4.3, 2 in <=2.9, and 1 in >=5.6mg/kg -30% Partial response Ovarian Cancer Patients Total (N = 99) Platinum Sensitive 21 (21
Slide 11: Luvelta Demonstrated Compelling Anti-Tumor Activity and Tolerable Safety Profile
Luvelta Demonstrated Compelling Anti-Tumor Activity and Tolerable Safety Profile Phase 1: Phase 1: Dose Escalation Dose Expansion Escalation Combo w/ Bevacizumab Signal Seeking Plus G-CSF (Neutropenia Mgt) N = 39 N = 18 N = 44 N = 16 Optimal dose range Tolerable and active Established FRα ≥25% PROC
Slide 12: Manageable Safety Profile with Low Discontinuation Rates, Consistent Across Indications
Manageable Safety Profile with Low Discontinuation Rates, Consistent Across Indications Treatment Emergent Adverse Events of Note Were Predictable and Manageable Neutropenia* Arthralgia Peripheral Neuropathy** • Primarily uncomplicated (febrile • Managed conservatively • Expected event with microtub
Slide 13: Prophylactic G-CSF Demonstrated Effective Reduction of Neutropenia
Use of Prophylactic G-CSF on Day 8 with Higher 5.2mg/kg Dose Demonstrated Effective Reduction of Neutropenia Maximum Reduction in Tumor Grade 3+ Neutropenia Cohort A1 vs. Cohort with G-CSF2 Target Lesions (N=16) 20% Cycle 1 Cycle 1+2 100% 80% 71.4% 66.7% Percent Patients 60% 73.7% -30% 90.6% Reducti
Slide 14: REFRαME-O1: Registration-directed Study for patients with PROC
REFRαME-O1: Registration-directed Study for patients with PROC • Part 1 – Fully enrolled (50 patients) in April 2024; patients now in follow up • Part 2 – Trial Open and Enrolling patients Phase 2: Phase 3: Eligibility Key Endpoints Dose Finding Randomized Trial • Platinum Resistant Ovarian Dose A:
Slide 15: REFRαME-P1: Addressing Unmet Patient Need + Accelerating PROC
REFRαME-P1: Addressing Unmet Patient Need + Accelerating PROC • Pediatric RAM AML – devastating disease impacting infants and toddlers: overall survival of 15-30% • Regulatory submission requirements in U.S. and Europe may be applicable for PROC submissions • Potential to receive priority review vou
Slide 16: Luvelta Plus Bevacizumab Combination Potentially Supports All-Comers Approach
Luvelta Plus Bevacizumab Combination Potentially Supports All-Comers Approach Phase 1b Response Data (Presented at ESMO 2024) 1 Phase 2 Expansion Cohort All Patients 4.3kg/mg Prior Bev FRαTPS • 23 patients enrolled to-date, (all doses) N=9 Naïve Treated <25% ≥25% including PSOC & PROC N=17 N=8 N=9 N
Slide 17: No New Safety Signals Observed in Luvelta Plus Bevacizumab Combination
No New Safety Signals Observed in Luvelta Plus Bevacizumab Combination TEAEs >25% Incidence (Any Grade and Grade ≥3) (N=18) Expected AEs Effectively Managed by Investigators n, (%) Any Grade Grade ≥3 Patients with ≥1 TEAE 18 (100) 13 (72) Neutropenia Neutropeniaa 13 (72) 8b (44) • Primarily uncompli
Slide 18: Luvelta Anti-Tumor Activity and Manageable Safety in Lower and/or Variable FRα Expression Tumors
Luvelta Demonstrated Compelling Anti-Tumor Activity and Manageable Safety Profile In Lower and/or Variable FRα Expression Tumors Endometrial RAM AML1 NSCLC N = 17 N = 25 Preclinical Evidence of anti-tumor activity Meaningful clinical responses, including complete Single dose and combination with PD-
Slide 19: FRα is Broadly Expressed Across Multiple Indications
19 mRNA expression level (RMA, log2) 6 4 8 10 12 endometrium (27) ovary (51) kidney (34) bile duct (8) colorectal (61) breast (58) pancreas (44) stomach (38) esophagus (25) lung_NSC (131) other (15) upper_aerodigestive (32) urinary tract (27) chondrosarcoma (4) glioma (62) liver (28) medulloblastoma
Slide 20: Research Portfolio – Poised to Generate INDs Over the Next 3 Years
Research Portfolio – Poised to Generate 3 INDs Over the Next 3 Years 20 NON CONFIDENTIAL
Slide 21: Exclusive Global Licensing Agreement with Ipsen for STRO-003 ROR1 Exatecan ADC
Exclusive Global Licensing Agreement with Ipsen for STRO-003 ROR1 Exatecan ADC Licensing Agreement Details Novel, Conjugation Site-Optimized ROR1 ADC Effective April 2024 • Ipsen secures exclusive global rights for development and ROR1 commercialization of STRO-003 • ~$90M in potential near-term pay
Slide 22: Sutro Well-Positioned to Lead Development of Next-Generation ADCs
Sutro Well-Positioned to Lead Development of Next-Generation ADCs Conjugated Antibody MODALITY ADC / ISAC iADC / ADC2 Bispecific ADC TARGET Dual 1. Mono- or Bispecific TAA Targeting Tumor Tumor Tumor Antigen Antigen Antigens Toolkit of Fit-to-Purpose Linker-Payloads • DNA targeting / tubulin targeti
Slide 23: Sutro’s Innovative Approach to Future ADC Development
Sutro’s Innovative Approach to Future ADC Development On-target Activity Improve- ments ADC Immunogenic Resistance Potency Cell Death Induction to Top1/Exatecan Dual Conjugate* DAR > 8* *Unique advantage of non-natural amino acid incorporation by Cell-free XpressCF® 23 NON CONFIDENTIAL
Slide 24: New Modality for Cold Tumors: Immunostimulatory Antibody Drug Conjugate (iADC)
New Modality for Cold Tumors: Immunostimulatory Antibody Drug Conjugate (iADC) Strategic iADC Collaboration • Combining a cytotoxin and immune modulator enabled by Sutro’s dual drug conjugation technology • Sutro has option to share costs/profits for U.S. product development • Sutro retained option
Slide 25: Express Cell-free Platform - Commercial GMP Scale Enabled in 2024
25 Express Cell-free Platform - Commercial GMP Scale Enabled in 2024 Approach / Feature Advantages Results • Stockpiled cell-free extract used to create a Cell-free extract and platform wide variety of proteins elements produced separately • Eliminates cell line development and cell Fully folded, ac
Slide 26: Well Capitalized with Strong Business Development Track Record
26 Well Capitalized with Strong Business Development Track Record ~$426M (1) in cash, cash equivalents & marketable securities and Vaxcyte common stock ~0.7M shares of ~$970M (2) Vaxcyte Funding generated from our (Nasdaq: PCVX) Jun 30, 2024 value collaborators included in above $ amount 1. Based on
Slide 27: Potential for Broad Patients Benefits with Significant Upcoming Milestones
Potential for Broad Patients Benefits with Significant Upcoming Milestones WORLDWIDE OR PHASE 3/ GEOGRAPHIC PROGRAM MODALITY/TARGET INDICATION DISCOVERY PRECLINICAL PHASE 1/1B PHASE 2 REGISTRATIONAL PARTNER SUTRO-LED PROGRAMS Ovarian Cancer Ovarian Cancer Luveltamab (bevacizumab combo) tazevibulin F
Slide 28: Experienced Leadership Team
Experienced Leadership Team William Newell, JD Anne Borgman, MD Barbara Leyman, PhD Ed Albini, MBA Chief Executive Officer and Chief Medical Officer Chief Business Development Officer Chief Financial Officer Member of the Board of Directors Hans-Peter Gerber, PhD Jane Chung, RPh Linda Fitzpatrick Ve
Sutro Biopharma — Investor Presentation (September 2024) on 6ix